CLINICAL_TRIALS
trial_result
· 2026-01-28
Clinical Trial Update: A Study of Bosmolisib (BR101801) in Participants With R/R PTCL. [Phase 2]
Summary
Phase 2 trial update for Bosmolisib (BR101801) in relapsed/refractory Peripheral T cell lymphoma; the study is currently not yet recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boryung Pharmaceutical Co., Ltd | Conditions: Peripheral T Cell Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING